• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Denmark·Financial Services·FPILIM.CO
Share

Formuepleje LimiTTellus Stocks

DKK 301.12Last Updated 30.06.2026

Issuer Rating

Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

DKK 151.70M

DKK 301.12
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Formuepleje LimiTTellus, an open-ended investment vehicle managed by Formuepleje A/S, operates as a global equity fund. Its primary aim is to deliver superior risk-adjusted returns through a focused portfolio of international stocks. The investment methodology emphasizes selecting companies with enduring business models and robust earnings power. A hallmark of the fund is its unique "LimiTT" mechanism, a specialized risk management strategy crafted to protect capital during substantial market corrections by strategically decreasing equity exposure. Moreover, the fund integrates Environmental, Social, and Governance (ESG) factors into its investment approach, classifying it under SFDR Article 8.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expens

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.07.2026 20:33

"A Key Source of Value and Risk": Wall Street's Top Tech Optimist Assesses SpaceX

01.07.2026 19:21

Companies laid off employees because of artificial intelligence. Some came to regret it.

01.07.2026 18:59

Meta will launch a cloud infrastructure business. It will compete with Google and Nebius

01.07.2026 18:47

BlackRock is betting on scarce resources in AI supply chains. How should you build your portfolio?

01.07.2026 18:39

Shares of pharmaceutical company Galderma plummeted: The U.S. has halted sales of a Botox generic

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026